EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has formed an Executive Scientific Advisory Board (SAB) chaired by Dr. Carl Regillo, a distinguished retinal surgeon. The SAB includes acclaimed members from prestigious institutions like Mayo Clinic and Duke University. This board aims to guide EyePoint's management in advancing its ocular product pipeline, notably the Phase 1 DAVIO trial for EYP-1901, a potential treatment for wet age-related macular degeneration. The board's collective expertise is expected to enhance the company's scientific strategy and improve patient outcomes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on August 4, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and recent business highlights. Investors can join the call by dialing (877)-312-7507 for domestic calls or (631)-813-4828 for international calls, using conference ID 1861354. The event will also be available via a live audio webcast on the company’s website. EyePoint is focused on innovative therapeutics for serious eye disorders and utilizes its proprietary Durasert® technology for extended drug delivery.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a nine-month extension of DEXYCU®'s pass-through payment status following a draft ruling by the Centers for Medicare and Medicaid Services (CMS). This extension, set to last until December 31, 2022, aids in the coverage of outpatient drugs during cataract surgeries, impacting approximately 60% of Medicare Part B patients. The final ruling from CMS is expected in November 2021. CEO Nancy Lurker expressed optimism about the extension, emphasizing its significance for DEXYCU's commercial strategy.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has reported positive safety results from its Phase 1 clinical trial of EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD). The trial involved 17 patients and showed no serious adverse events after 30-day follow-ups. The company anticipates releasing interim efficacy results in Q4 2021 and plans to initiate trials for diabetic retinopathy and retinal vein occlusion. EYP-1901 utilizes proprietary Durasert® technology for sustained drug delivery, demonstrating the company's commitment to advancing eye disorder treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that the American Medical Association accepted a new Category III CPT code (0X78T) for drug administration in the eye, effective January 1, 2022. This code provides a reimbursement pathway for DEXYCU, the first FDA-approved sustained-release intracameral steroid for postoperative inflammation treatment. The approval is seen as a significant step toward increased adoption of DEXYCU, enhancing its market presence and financial prospects.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its inclusion in the small-cap Russell 2000® Index and the broader Russell 3000® Index, effective June 28, 2021. This addition reflects the company’s position among approximately 2,000 smaller companies based on market capitalization.
The Russell indexes are critical benchmarks for investment strategies, managing $10.6 trillion in assets. EyePoint focuses on therapeutics for serious eye disorders, leveraging its proprietary Durasert® technology and two commercial products, YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will have CEO Nancy Lurker speak at the Jefferies Healthcare Conference on June 2, 2021, at 9:30 a.m. ET. The session will explore the company's commitment to developing therapies for serious eye disorders, including innovations like EYP-1901, a treatment for wet age-related macular degeneration. Attendees can access a live webcast and a 90-day archive via EyePoint's website. The company also markets YUTIQ and DEXYCU for eye disorder treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced successful enrollment completion for its Phase 1 trial of EYP-1901, a potential twice-yearly treatment for wet age-related macular degeneration (wet AMD). The trial includes dose escalation for patients previously responsive to anti-VEGF therapies. Interim data is expected in Q4 2021. EYP-1901 employs EyePoint’s Durasert technology for sustained delivery, potentially improving treatment outcomes for patients. The company aims to explore additional applications for EYP-1901, including diabetic retinopathy.
EyePoint Pharmaceuticals (EYPT) reported a productive first quarter of 2021, achieving net product revenues of $6.8 million, a 45% increase from $4.7 million in Q1 2020. The company completed a $115.1 million follow-on financing, enhancing its development pipeline. The Phase 1 DAVIO study for EYP-1901 targeting wet AMD is on track for initial data in Q4 2021. However, total net revenue declined slightly to $7.3 million from $7.5 million year-over-year. The net loss was $12.3 million, or ($0.50) per share, an improvement from a loss of $13.2 million in the same quarter last year.
EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to host a conference call on May 5, 2021, at 8:30 a.m. ET to announce its Q1 2021 financial results and discuss corporate developments. The call will be accessible via phone and a live webcast on the company’s website. EyePoint focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its commercial products include YUTIQ® for chronic uveitis and DEXYCU® for postoperative inflammation.